REGN - Regeneron Pharmaceuticals, Inc.
About Regeneron Pharmaceuticals, Inc. (https://www.regeneron.com)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Leonard S. Schleifer | Co-Founder, President, Chief Executive Officer & Co-Chairman | 1953 | $7,280,549 USD |
| George D. Yancopoulos | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 1960 | $6,949,469 USD |
| Joseph J. LaRosa | Executive Vice President, General Counsel & Secretary | 1959 | $2,959,826 USD |
| Daniel Van Plew | Executive Vice President and GM of Industrial Operations & Product Supply | 1973 | $2,030,778 USD |
| Andrew J. Murphy | Executive Vice President of Research & Co-Chief Scientific Officer | 1958 | $1,727,634 USD |
| Marion E. McCourt | Executive Vice President of Commercial | 1960 | $1,500,262 USD |
| Christopher R. Fenimore | Executive Vice President of Finance & Chief Financial Officer | 1971 | $1,485,636 USD |
| Hanne Bak | Senior Vice President of Product, Analytical & Process Development | – | – |
| John Lin | Senior VP of Antibody Technology, Oncology & Research | – | – |
| Maya Bermingham | Senior Vice President of Public Policy & Government Affairs | – | – |
| Melissa Lozner | Senior Vice President & Chief Compliance Officer | – | – |
| Ned Braunstein | Executive Vice President of Regulatory Affairs and Global Patient Safety & Development Quality | – | – |
| Rajesh Ahuja | Senior Vice President of Quality Assurance & Operations | – | – |
| Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis | – | – |
| Ryan Steinberger | Executive VP, Chief Digital & Technology Officer | – | – |
| Sally A. Paull | Executive Vice President of Human Resources | – | – |